Otsuka Signs On To Promote Two UCB Products Just In Time For Possible Raised Safety Concerns
This article was originally published in PharmAsia News
Executive Summary
Otsuka and UCB have agreed to a co-development and co-promotional deal for the Belgium firm's antiepileptic Keppra (levetiracetam) and anti-TNF alpha drug Cimzia (certolizumab pegol) for the Japanese market while both products currently face potential safety hurdles in the U.S
You may also be interested in...
Otsuka Searches For Value In Portfolio Through Patient Compliance Technology
Alliance with Lundbeck emphasizes search for innovation in all corners of CNS research.
China Study Finds Cilostazol Better Than Aspirin After Stroke
Chinese researchers have determined cilostazol, an anti-clotting drug, may be safer than aspirin for some people who have had a stroke. Such patients are considered at higher risk of a cerebral hemorrhage, but the anti-platelet drug appears to have a long-term effect in low doses. The researchers' work was published online by the journal The Lancet Neurology. Cilostazol is made in China by Otsuka Pharmaceutical under the brand Pletal. (Click here for more
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).